Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.
Arena's Ralinepag Positive in Phase II PAH Study, Shares Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.
Novartis' Cosentyx Superior to Stelara in Psoriasis Study
by Zacks Equity Research
Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Microsoft Unveils Software to Enhance Employee Productivity
by Zacks Equity Research
Microsoft Corp. (MSFT) recently launched its long awaited employee performance analysis software called Workplace Analytics.
Geron Stock Up Almost 40% So Far This Year After '16 Decline
by Zacks Equity Research
Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.
Cardiome's Partner SteadyMed Submits NDA for PAH Injection
by Zacks Equity Research
Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).
Alkermes Presents Phase III Data on Schizophrenia Candidate
by Zacks Equity Research
Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.
Arena Ends Study on Extended Release Formulation of PAH Drug
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.
Top Research Reports for JNJ, AT&T & Lockheed Martin
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), AT&T (T), and Lockheed Martin (LMT).
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
How to Interpret Big Oil's Support for a Carbon Tax
by Nilanjan Choudhury
Surprisingly, some of the biggest energy companies have joined the call advocating for a progressively rising carbon tax.
Better Days Ahead for the Pharma Sector?
by Arpita Dutt
Sales, R&D, strong results, and a higher number of FDA approvals.
Gilead's (GILD) HCV Drug Application Accepted in the EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
Healthcare ETF (IYH) Hits New 52-Week High
by Sweta Killa
This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?
Here's Why Geron (GERN) is a Good Stock to Invest in Now
by Zacks Equity Research
Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.
Fitch Sees Fastest Global Growth in 10 Years: ETFs To Buy
by Zacks Equity Research
Credit rating agency Fitch expects the global growth to reach 2.9% in 2017 and 3.1% in 2018.
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
by Zacks Equity Research
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older
Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago
by Zacks Equity Research
Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Company News for June 19, 2017
by Zacks Equity Research
Companies in the News are: FNSR,JNJ,BHP,DOW,DD
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.
J&J's Invokana Lowers Heart Issues, Raises Amputation Risk
by Zacks Equity Research
Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.